The apolipoprotein E (APOE) ∊4 allelle is a well-established risk factor for cognitive decline. Racial factors may mitigate its effects. However, APOE ∊4 has similar effects even among different racial groups. The APOE genotype in patients with Alzheimer's disease may influence therapeutic decisions.
CorderE.H., SaundersA.M., StrittmatterW.J., SchmechelD.E., GaskellP.C., SmallG.W., RosesA.D., HainesJ.L., Pericak-VanceM.A.Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science1993, 261(5123): 921–923.
3.
RosesA.D.Apolipoprotein E affects the rate of Alzheimer disease expression: β-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease. J Neuropathol Exp Neurol1994, 53(5): 429–437.
4.
StrittmatterW.J., SaundersA.M., SchmechelD., Pericak-VanceM., EnghildJ., SalvesenG.S., RosesA.D.Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA1993, 90(5): 1977–1981.
5.
FarrerL.A., CupplesL.A., HainesJ.L., HymanB., KukullW.A., MayeuxR., MyersR.H., Pericak-VanceM.A., RischN., van DuijnC.M.Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. JAMA1997, 278(16): 1349–1356.
6.
DavidsonY., GibbonsL., PritchardA., HardicreJ., WrenJ., StopfordC., JulienC., ThompsonJ., PaytonA., Pickering-BrownS.M., PendletonN., HoranM.A., BurnsA., PurandareN., LendonC.L., NearyD., SnowdenJ.S., MannD.M.A.Apolipoprotein E ∊4 allele frequency and age at onset of Alzheimer's disease. Dement Geriatr Cogn Disord2007, 23(1): 60–66.
7.
ResnickS.M., BilgelM., MoghekarA., AnY., CaiQ., WangM.C., ThambisettyM., PrinceJ.L., ZhouY., SoldanA., WongD.F., O'BrienR.J., FerrucciL., AlbertM.S.Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts. Neurobiol Aging2015, 36(8): 2333–2339.
8.
LangeK.L., BondiM.W., SalmonD.P., GalaskoD., DelisD.C., ThomasR.G., ThalL.J.Decline in verbal memory during preclinical Alzheimer's disease: Examination of the effect of APOE genotype. J Int NeuropsycholSoc2002, 8(7): 943–955.
9.
WisdomN.M., CallahanJ.L., HawkinsK.A.The effects of apolipoprotein E on non-impaired cognitive functioning: A meta-analysis. Neurobiol Aging2011, 32(1): 63–74.
10.
ThorvaldssonV., NordlundA., ReinvangI., BlennowK., ZetterbergH., WallinA., JohanssonB.Memory in individuals with mild cognitive impairment in relation to APOE and CSF Aβ42. Int Psychogeriatr2010, 22(4): 598–606.
11.
HardyJ., AllsopD.Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci1991, 12: 383–388.
12.
BueeL., BussièreT., Buée-ScherrerV., DelacourteA., HofP.R.Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev2000, 33(1): 95–130.
13.
Lasagna-ReevesC.A., Castillo-CarranzaD.L., SenguptaU., Guerrero-MunozM.J., KiritoshiT., NeugebauerV., JacksonG.R., KayedR.Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep2012, 2: 700.
14.
LehtovirtaM., SoininenH., HelisalmiS., MannermaaA., HelkalaE.L., HartikainenP., HanninenT., RyynanenM., RiekkinenP.J.Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: Relation to apolipoprotein E polymorphism. Neurology1996, 46(2): 413–419.
15.
WolkD.A., DickersonB.C.The Alzheimer's Disease Neuroimaging Initiative. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. Proc Natl Acad Sci USA2010, 107(22): 10256–10261.
16.
JonkerC., SchmandB., LindeboomJ., HavekesL.M., LaunerL.J.Association between apolipoprotein E ∊4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia. Arch Neurol1998, 55(8): 1065–1069.
17.
van der FlierW.M., SchoonenboomS.N.M., PijnenburgY.A.L., FoxN.C., ScheltensP.The effect of APOE genotype on clinical phenotype in Alzheimer disease. Neurology2006, 67(3): 526–527.
MarraC., BizzarroA., DanieleA., De LucaL., FerraccioliM., ValenzaA., BraheC., TizianoF.D., GainottiG., MasulloC.Apolipoprotein E ∊4 allele differently affects the patterns of neuropsychological presentation in early- and late-onset Alzheimer's disease patients. Dement Geriatr Cogn Disord2004, 18(2): 125–131.
20.
BretskyP., GuralnikJ.M., LaunerL., AlbertM., SeemanT.E.The role of APOE-∊4 in longitudinal cognitive decline: MacArthur studies of successful aging. Neurology2003, 60(7): 1077–1081.
21.
SmithG.E., BohacD.L., WaringS.C., KokmenE., TangalosE.G., IvnikR.J., PetersenR.C.Apolipoprotein E genotype influences cognitive ‘phenotype’ in patients with Alzheimer's disease but not in healthy control subjects. Neurology1998, 50(2): 355–362.
22.
WilsonR.S., SchneiderJ.A., BarnesL.L., BeckettL.A., AggarwalN.T., CochranE.J., Berry-KravisE., BachJ., FoxJ.H., EvansD.A., BennettD.A.The apolipoprotein E ∊4 allele and decline in different cognitive systems during a 6-year period. Arch Neurol2002, 59(7): 1154–1160.
23.
KullerL.H., ShemanskiL., ManolioT., HaanM., FriedL., BryanN., BurkeG.L., TracyR., BhadeliaR.Relationship between ApoE, MRI findings, and cognitive function in the Cardiovascular Health Study. Stroke1998, 29(2): 388–398.
24.
GreenR.C., CupplesL.A., GoR., BenkeK.S., EdekiT., GriffithP.A., WilliamsM., HippsY., Graff-RadfordN., BachmanD., FarrerL.A.The MIRAGE Study Group. Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA2002, 287(3): 329–336.
25.
MurrellJ.R., PriceB., LaneK.A., BaiyewuO., GurejeO., OgunniyiA., UnverzagtF.W., Smith-GambleV., GaoS., HendrieH.C., HallK.S.Association of apolipoprotein E genotype and Alzheimer disease in African Americans. Arch Neurol2006, 63(3): 431–434.
26.
HironoN., HashimotoM., YasudaM., KazuiH., MoriE.Accelerated memory decline in Alzheimer's disease with apolipoprotein ∊4 allele. J Neuropsychiatry Clin Neurosci2003, 15(3): 354–358.
27.
YangCH, WuS.J., ChouM.C., ChenC.H., TaiS.Y., HuangS.W., YangY.H.Effects of the Apolipoprotein E genotype on the therapeutic response in Alzheimer's disease patients in Taiwan. J Dis Markers2015, 2(1): 1019.
28.
van der VliesA.E., PijnenburgY.A.L., KoeneT., KleinM., KokA., ScheltensP., van der FlierW.M.Cognitive impairment in Alzheimer's disease is modified by APOE genotype. Dement Geriatr Cogn Disord2007, 24(2): 98–103.
29.
El HajM., AntoineP., AmouyelP., LambertJ.C., PasquierF., KapogiannisD.Apolipoprotein E (APOE) ∊4 and episodic memory decline in Alzheimer's disease: A review. Ageing Res Rev2016, 11(27): 15–22.
